Directeur, Programme d'évaluation, d'intervention et de prévention des psychoses (PEPP-Montréal), Institut Douglas
ashok_dot_malla_At_douglas_dot_mcgill_dot_ca |
2002
Malla A., Mittal C., Lee M., Scholten D. J., Assis L., Norman R. M. (2002). Computed tomography of the brain morphology of patients with first-episode schizophrenic psychosis, J Psychiatry Neurosci, 27(5), 350-8.
Malla A., Norman R. M., Manchanda R., Ahmed M. R., Scholten D., Harricharan R., Cortese L., Takhar J. (2002). One year outcome in first episode psychosis: influence of DUP and other predictors, Schizophr Res, 54(3), 231-42.
Malla A., Norman R. M., Manchanda R., McLean T. S., Harricharan R., Cortese L., Townsend L. A., Scholten D. J. (2002). Status of patients with first-episode psychosis after one year of phase-specific community-oriented treatment, Psychiatr Serv, 53(4), 458-63.
Malla A., Norman R. M., Manchanda R., Townsend L. (2002). Symptoms, cognition, treatment adherence and functional outcome in first-episode psychosis, Psychol Med, 32(6), 1109-19.
Malla A., Takhar J. J., Norman R. M., Manchanda R., Cortese L., Haricharan R., Verdi M., Ahmed R. (2002). Negative symptoms in first episode non-affective psychosis, Acta Psychiatr Scand, 105(6), 431-9.
Norman R. M., Malla A. (2002). Examining adherence to medication and substance use as possible confounds of duration of untreated psychosis, J Nerv Ment Dis, 190(5), 331-4.
Norman R. M., Malla A., McLean T. S., McIntosh E. M., Neufeld R. W., Voruganti L. P., Cortese L. (2002). An evaluation of a stress management program for individuals with schizophrenia, Schizophr Res, 58(2-3), 293-303.
Theberge J., Bartha R., Drost D. J., Menon R. S., Malla A., Takhar J., Neufeld R. W., Rogers J., Pavlosky W., Schaefer B., Densmore M., Al-Semaan Y., Williamson P. C. (2002). Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers, Am J Psychiatry, 159(11), 1944-6.
Townsend L. A., Norman R. M., Malla A., Rychlo A. D., Ahmed R. R. (2002). Changes in cognitive functioning following comprehensive treatment for first episode patients with schizophrenia spectrum disorders, Psychiatry Res, 113(1-2), 69-81.